Blackstone (NYSE: BX), the world’s largest alternative asset manager, is expanding its presence in the life sciences sector with a new multibillion-dollar fund dedicated to drug development.
As of today, all clinical trials in the European Union (EU), including those that were approved under the previous legal framework, the Clinical Trials Directive (CTD), are governed by the Clinical ...